Edinburgh Research Explorer

Benchmarking to the Gold Standard: Hyaluronan-oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture

Benchmarking to the Gold Standard: Hyaluronan-oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture
--Manuscript Draft--

Manuscript Number:	adma.201901166R1
Full Title:	Benchmarking to the Gold Standard: Hyaluronan-oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture
Article Type:	Communication
Section/Category:	
Keywords:	hyaluronic acid; hydrogels; drug screening; breast cancer; 3D cell culture
Corresponding Author:	Molly S. Shoichet, Ph.D. University of Toronto Toronto, CANADA
Additional Information:	
Question	Response
Please submit a plain text version of your cover letter here.	Molly Shoichet, PhD, FRS, O.C., O.Ont. University Professor Molly.shoichet@utoronto.ca 416-978-1460

Molly Shoichet, PhD, FRS, O.C., O.Ont.
University Professor
Molly.shoichet@utoronto.ca
416-978-1460

May 10, 2019

Floriano Cuccureddu, Editor
Advanced Materials

Re: Communication, No. adma.201901166
"Benchmarking to the Gold Standard: Hyaluronan-oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture"

Dear Dr. Cuccureddu:

We want to thank you and the reviewers for thoughtful consideration of our manuscript. We must admit that we were surprised by your decision to reject our paper based on the reviews, which required only clarification of the text and no new experiments. Moreover, the Reviewers were generally positive, highlighting the importance of validating novel hydrogels for 3D culture – something that we rarely see in the published literature. This burgeoning field is now exploding to include organoid culture, yet the same poor choice of Matrigel is being pursued therein. We have a unique and innovative material that enables critical questions in biology to be answered.

While Reviewer #1 suggested that our paper be considered in a sister journal, Reviewer #2 indicated that our paper should be published in this journal; both Reviewers 1 and 2 rated the originality of our submission with an acceptable level of new results; Reviewer #1 rated the scientific and technical content as fully consistent and accurate while Reviewer #2 highlighted only minor inconsistencies; both Reviewers 1 and 2 found the length concise and correct.

We have prepared a detailed response and revised our manuscript accordingly.

	We respectfully request that you re-consider your decision and send our revised paper out for re-review. We are confident that this revised paper is clearer and stronger and that the novel chemistry described makes Advanced Materials the most appropriate journal for its publication. Sincerely, Molly Shoichet, PhD, FRS, O.C., O.Ont. University Professor Tier 1 Canada Research Chair, Tissue Engineering
Do you or any of your co-authors have a conflict of interest to declare?	No. The authors declare no conflict of interest.
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Toronto
Corresponding Author's Secondary Institution:	
First Author:	Alexander E. G. Baker
First Author Secondary Information:	
Order of Authors:	Alexander E. G. Baker
	Laura C. Bahlmann
	Roger Y. Tam
	Jeffrey C. Liu
	Ahil N. Ganesh
	Nikolaos Mitrousis
	Richard Marcellus
	Melanie Spears
	John M. S. Bartlett
	David W. Cescon
	Gary D. Bader
	Molly S. Shoichet, Ph.D.
Order of Authors Secondary Information:	
Abstract:	Many 3D in vitro models induce breast cancer spheroid formation; however, this alone does not recapitulate the complex in vivo phenotype. To effectively screen therapeutics, we urgently need to validate in vitro cancer spheroid models against the gold standard of xenografts. We designed a new oxime-crosslinked hyaluronan (HA) hydrogel, manipulating gelation rate and mechanical properties to grow breast cancer spheroids in 3D. Our HA-oxime breast cancer model maintains the gene expression profile most similar to that of tumour xenografts based on a pan-cancer gene expression profile (comprising 730 genes) of 3 different human breast cancer subtypes compared to Matrigel or conventional 2D culture. Differences in gene expression between breast cancer cultures in HA-oxime versus Matrigel or 2D were confirmed for 12 canonical pathways by gene set variation analysis. Importantly, drug response was dependent on the culture method. Breast cancer cells responded better to the Rac inhibitor (EHT-1864) and the PI3K inhibitor (AZD6482) when cultured in HA-oxime versus Matrigel. This study demonstrates, for the first time, the superiority of an HA-based hydrogel as a platform for in vitro breast cancer culture of both primary, patient-derived cells and cell lines, and provides a hydrogel culture model that closely matches

	that in vivo.

Benchmarking to the Gold Standard: Hyaluronan-oxime Hydrogels Recapitulate Xenograft Models with *In Vitro* Breast Cancer Spheroid Culture

Alexander E. G. Baker, Laura C. Bahlmann, Roger Y. Tam, Jeffrey C. Liu, Ahil N. Ganesh, Nikolaos Mitrousis, Richard Marcellus, Melanie Spears, John M. S. Bartlett, David W. Cescon, Gary D. Bader, Molly S. Shoichet[*]

Dr. A. E. G. Baker, L. C. Bahlmann, Dr. R. Y. Tam, Dr. J. C. Liu, Dr. A. N. Ganesh, Dr. N. Mitrousis, Prof. G. D. Bader, Prof. M. S. Shoichet
The Donnelly Centre, University of Toronto, Toronto, 160 College St, Ontario, M5S 3E1, Canada

Dr. A. E. G. Baker, Dr. R. Y. Tam, Dr. A. N. Ganesh, Prof. M. S. Shoichet
Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, Ontario, M5S 3E5, Canada

Dr. A. E. G. Baker, L. C. Bahlmann, Dr. R. Y. Tam, Dr. J. C. Liu, Dr. A. N. Ganesh, Dr. N. Mitrousis, Prof. M. S. Shoichet
Institute of Biomaterials and Biomedical Engineering, 164 College Street, Toronto, Ontario, M5S 3G9, Canada

Dr. R. Marcellus, Dr. M. Spears, Dr. J. M. S. Bartlett
Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Toronto, Ontario, M5G 0A3, Canada

Dr. M. Spears
Department of Laboratory Medicine and Pathology, University of Toronto, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada

Dr. D. W. Cescon
Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, Ontario, M5G 2C1, Canada

Prof. M. S. Shoichet
Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario, M5S 3H6, Canada

* To whom all correspondence should be addressed:

e-mail: molly.shoichet@utoronto.ca

Abstract

Many 3D *in vitro* models induce breast cancer spheroid formation; however, this alone does not

recapitulate the complex *in vivo* phenotype. To effectively screen therapeutics, we urgently need

to validate *in vitro* cancer spheroid models against the gold standard of xenografts. We designed a new oxime-crosslinked hyaluronan (HA) hydrogel, manipulating gelation rate and mechanical properties to grow breast cancer spheroids in 3D. Our HA-oxime breast cancer model maintains the gene expression profile most similar to that of tumour xenografts based on a pan-cancer gene expression profile (comprising 730 genes) of 3 different human breast cancer subtypes compared to Matrigel or conventional 2D culture. Differences in gene expression between breast cancer cultures in HA-oxime versus Matrigel or 2D were confirmed for 12 canonical pathways by gene set variation analysis. Importantly, drug response was dependent on the culture method. Breast cancer cells responded better to the Rac inhibitor (EHT-1864) and the PI3K inhibitor (AZD6482) when cultured in HA-oxime versus Matrigel. This study demonstrates, for the first time, the superiority of an HA-based hydrogel as a platform for *in vitro* breast cancer culture of both primary, patient-derived cells and cell lines, and provides a hydrogel culture model that closely matches that *in vivo*.

Main

Despite improvements in initial target identification using computational approaches,[1] and several proposed hydrogels to culture cells for the *in vitro* stage of drug discovery,[2] two-dimensional (2D) culture on tissue culture poly(styrene) (TCPS) continues to be used to screen cancer therapeutics. 2D culture does not represent the *in vivo* microenvironment either mechanically or biochemically, thereby leading to false positive (and likely false negative) drug hits.[3] *In vivo* xenograft tumour models recapitulate human disease more faithfully, but are costly, time-consuming and complicated by the use of immunocompromised mice.[4] The inaccurate but rapid and simple method of testing drugs in 2D coupled with the complexity of xenograft models, has motivated the development of more representative three-dimensional (3D) culture platforms.

2

A suitable 3D culture system must be sufficiently stable for drug screening and benchmarked against gold standard *in vivo* xenograft tumour models.[5] The limited availability of such 3D models results in the continued reliance on 2D culture, even with the recognition that 2D culture does not accurately predict *in vivo* outcomes.

Unlike 2D culture, where breast epithelial cancer cells form a monolayer, 3D models of cancer recapitulate many disease characteristics such as formation of cancer spheroids with tight junctions, and inclusion of key biochemical and mechanical cues of the native extracellular matrix (ECM).[6] Typically, cancer spheroids are formed by growing epithelial cancer cells in 3D using non-adherent conditions. This method is rapid and provides remarkable control of the spheroid size;[7] yet, unsurprisingly, the gene expression profiles of these cancer spheroids (CS) formed by aggregation resemble cells cultured in 2D more closely than those of xenograft tumours.[8] Therefore, spheroid formation alone does not recapitulate the *in vivo* microenvironment.[9] Non-adherent conditions lack critical ECM components, which both affect cell function through integrin-mediated signaling pathways, such as β1, and influence drug effectiveness.[10]

Laminin-rich extracellular matrices, such as Matrigel®, which is derived from the Engelbreth-Holm-Swarm murine sarcoma, are favored for 3D cell culture as they contain some physiologically relevant ECM proteins that mimic the breast tumour microenvironment.[11] However, Matrigel is ill-defined,[12] and its composition, physicochemical and biomechanical properties have limited tunability.[13] Moreover, Matrigel does not include key matrix components found in the breast cancer microenvironment such as hyaluronan (HA), which is produced by tumour and stromal cells and is linked to disease progression.[14] The diversity of cell-surface integrin expression and tumour microenvironment properties across breast cancer subtypes require a model that is tunable to meet these complexities.[15]

The majority of chemically crosslinked hydrogels utilize chemistries that have rapid reaction kinetics,[16] such as the thiol-Michael addition ligation,[17] and limit uniform cell encapsulation, making reproducible *in vitro* cell culture challenging. Moreover, many scaffold components need to be stored under inert gas due to air-sensitive functional groups, such as thiols, and/or require external stimuli to promote crosslinking, which complicates scale up.[18, 19] To achieve a more controlled system for cell encapsulation, we combined fast-reacting HA-aldehyde and slow-reacting HA-ketone with poly(ethylene glycol) (PEG)-oxyamine to create defined 3D hydrogels via oxime click chemistry. Oxime ligation is hydrolytically stable, thereby allowing long-term encapsulation of breast cancer cells – a key advance over current strategies that are inherently limited by reversible reactions of hydrazone or Diels-Alder chemistries for crosslinking.[20, 21] In addition, the oxime chemistry is insensitive to oxidation, facile to use and enables controlled gelation rates, which is typically not possible with other click chemistry reactions.[18] We used these newly synthesized oxime-crosslinked HA hydrogels to benchmark the gene expression of breast cancer cells against tumour xenografts grown in mice and evaluate drug response in comparison with conventional culture in Matrigel and 2D TCPS (Fig. 1a).

Synthesis of HA-oxime Hydrogels

We synthesized HA-oxime gels with HA-ketone (HAK), HA-aldehyde (HAA) and PEG-oxyamine, each component of which first needed to be synthesized. HAK was synthesized, for the first time, in a two-step reaction: (1) amide coupling of 3-(2-methyl-1,3-dioxolan-2-yl)propan-1-amine with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) as an activator and (2) acid-catalyzed ketone deprotection (Fig. 1b). We found the substitution of ketone to be tunable between $28 \pm 3\%$ and $55 \pm 2\%$ by increasing the equivalents of DMTMM from 1.0 to 2.5, respectively (Fig. S1). We chose to use HAK with approximately 40% ketone

4

substitution to produce hydrogels because it was water soluble and easy to handle. Similarly, we synthesized aldehyde-modified HA (HAA) in two steps: (1) amidation of carboxylic acid groups on HA with DMTMM/aminoacetaldehyde dimethyl acetal, and (2) deprotection of the resulting HA-acetal with aqueous acid (Fig. 1c, Fig S2). The PEG-substituted oxyamine crosslinker was prepared from either 4-arm PEG-tetramine or 2-arm PEG-bisamine and (boc-aminooxy)acetic acid with carbodiimide coupling followed by acid-catalyzed deprotection to yield PEGOA$_4$ and PEGOA$_2$, respectively (Fig. S2).

We combined HAK and HAA with PEGOA$_4$ and laminin (a common extracellular matrix protein) to produce crosslinked hydrogels with tunable biochemical properties to grow breast cancer spheroids (Fig. 1d). To show that both HAK and HAA biopolymers were crosslinked with PEG-oxyamine, we compared the stability of hydrogels comprised of equal weight percent of either HAK/HAA or unmodified-HA/HAA crosslinked with PEG-oxyamine: HAK/HAA hydrogels remained stable over at least 28 days (with less than 5% decrease in mass) whereas gels formed from HA/HAA slowly dissociated, losing $50 \pm 2\%$ of their mass between day 1 and 28, reflecting the dissolution of uncrosslinked HA (Fig. S3). Gels crosslinked with four-armed PEGOA$_4$ swelled significantly less than those crosslinked with bifunctional PEGOA$_2$ (Fig. S3). Although both remained intact over four weeks, we used PEGOA$_4$ in all subsequent experiments because the increased swelling of PEGOA$_2$ crosslinked gels would alter hydrogel mechanical properties and hence cell phenotype.[22]

Tunable Gelation of HA-oxime Hydrogels Influences 3D Cell Distribution

To achieve uniform 3D cell distribution, hydrogels must form rapidly enough to avoid cell aggregation due to gravity during gelation, but slow enough for practical use. HAA only crosslinked hydrogels (0:1 HAK:HAA) formed too quickly for cell encapsulation, requiring cells

to be cultured on top of those gels versus within.[21] In contrast, hydrogels synthesized with only HAK (1:0, HAK:HAA) and PEGOA$_4$ formed too slowly, with gelation at 87 ± 11 min. Consequently, when single breast cancer cells were encapsulated in HAK-only HA-oxime gels, cells accumulated in the bottom of the well, due to the slow crosslinking reaction between ketones and oxyamines (Fig. 1e). We used rheology to characterize the gelation rate of HA-oxime hydrogels with varying HAK:HAA mass ratios (Fig. S4). The gelation rate increased significantly with an increasing amount of HAA (Fig. 1f). HA-oxime hydrogels produced with HAK:HAA mass ratios of either 7:1 or 3:1, at a constant oxyamine to ketone/aldehyde mole ratio of 0.60, resulted in mean gelation times of 35 and 25 min, respectively. At higher weight percentages of the faster gelling HAA (HAK:HAA of 1:1), the resulting crosslinked gel formed too rapidly for quantification by rheology. We used HAK:HAA of 3:1 in subsequent assays and found a uniform distribution of viable cells (Fig. S5). This uniform distribution was maintained for a longer time when cells were grown in HA-oxime hydrogels versus those in Matrigel or a commercially available HA-based hydrogel, HyStem-C (HA-thiol/gelatin-thiol crosslinked with PEG diacrylate) (Fig. S5c).

Composition-controlled Mechanical Properties and Enzyme-specific Degradation of HA-oxime Hydrogels

We were interested in understanding the mechanical tunability of HA-oxime hydrogels in relation to Matrigel, the current standard for 3D cell and organoid culture. Matrigel compositions, purchased with protein concentrations of 8.50 and 18.43 mg·mL^{-1}, had compressive moduli of 0.9 $\pm$ 0.7 kPa and 1.6 $\pm$ 0.4 kPa, respectively, which were not significantly different from each other (Fig. 1g). These formulations are typically used for *in vitro* culture and underscore the limited mechanical tunability offered by Matrigel.[23] In contrast, the stiffness of HA-oxime hydrogels

varied with the ratio of HAK to HAA. HA-oxime hydrogels are highly tunable over 2 orders of magnitude, between 0.3 and 15 kPa, by either varying the crosslinking density or the weight percent of HA (Fig. S6). This range covers the stiffness reported for mouse mammary tumours (~1.5-4.0 kPa), and human breast cancer tissue (~5-16 kPa), as measured by compression and atomic force microscopy, respectively.[24, 25]

HAK-only (1.35 wt%) hydrogels were significantly stiffer (15 ± 1 kPa) than HAA-only (1.35 wt%) hydrogels (5.5 ± 0.4 kPa) at a constant mole ratio (0.80) of oxyamine to ketone/aldehyde (Fig. S6). We attributed this difference in modulus of HAK-oxime and HAA-oxime hydrogels to the difference in molar mass. While we started with the same molar mass of HA, synthesis of HAK resulted in a molar mass of 311 kg·mol^{-1} whereas that of HAA resulted in a molar mass of 122 kg·mol^{-1} as measured by gel permeation chromatography. Importantly, there was no change in oxyamine to oxime conversion with all HAK and HAA formulations, as quantified by ^{1}H NMR spectroscopy (Fig. S7), further indicating that the molar mass difference accounted for the difference in compressive modulus. The stiffness of gel formulations with 3:1 and 1:1 HAK:HAA weight ratios were not statistically different from Matrigel, so we used 3:1 ratio for future experiments as it was easier to handle. We found that these HA-oxime gels were stable for 28 days when swollen in PBS or when treated with collagenase and degraded only in the presence of hyaluronidase, highlighting the enzyme-specific degradability (Fig. 1h). Importantly, breast cancer cells are known to produce hyaluronidase, which allows dynamic, cell-based spatiotemporal remodeling of the HA-oxime hydrogels during cell growth.[26]

7

Figure 1. Synthesis and characterization of the HA-oxime hydrogel to model breast cancer in vitro.

(a) The overall goal was to benchmark the gene expression profile of cells cultured in vitro in our

novel HA-oxime hydrogels relative to conventional culture in either Matrigel or 2D tissue culture

polystyrene (TCPS) to those cells grown in vivo. This methodology allows us to identify pathways

that can then be targeted in drug screening assays. (b) Synthesis of HA-ketone using DMTMM coupling to HA with 3-(2-methyl-1,3-dioxolan-2-yl)propan-1-amine followed by acid-catalyzed deprotection, and neutralization. (c) Synthesis of HA-aldehyde using DMTMM coupling with aminoacetaldehyde dimethyl acetal followed by acid-catalyzed deprotection, and neutralization. (d) HA-oxime crosslinked hydrogels comprised of HA-ketone (HAK, red), HA-aldehyde (HAA, blue), and poly(ethylene glycol)-tetraoxyamine (PEGOA$_4$, orange) and formed in the presence of laminin (green) and breast cancer cells (tan), which resulted in uniformly distributed cells. (e) Distribution of encapsulated MDA-MB-468 cells after 24 h in HA-oxime hydrogels: in HAK crosslinked gels, cells aggregate at the bottom of the well due to the slow gelation whereas in HAK:HAA (3:1 mass ratio), cells are evenly distributed. Cells were stained for viability with calcein AM (live, green) and ethidium homodimer-1 (dead, red); scale bar represents 200 μm (n = 3 independent experiments; mean + s.d. plotted, ***p<0.001, one-way ANOVA, Tukey's post-hoc test). (f) Gelation time of HA-oxime hydrogels crosslinked with PEGOA$_4$ (n = 3, mean + s.d., ***p<0.001, one-way ANOVA, Tukey's post-hoc test). (g) Compressive modulus of HA-oxime hydrogels compared to growth factor reduced Matrigel (n = 4, mean + s.d. plotted, *p<0.05; **p<0.01, one-way ANOVA, Tukey's post-hoc test). The red shaded area represents the range in stiffness of mouse tumours reported in the literature.[24] (h) HA-oxime hydrogel prepared from 3:1 HA-ketone (0.90 wt%) and HA-aldehyde (0.30 wt%) crosslinked with PEGOA$_4$ (1.04 wt%) was stable over 28 days at 37 °C in Hank's balanced salt solution (HBSS) and in the presence of collagenase, but degraded in the presence of hyaluronidase. The percent of remaining hydrogel was determined from the mass measurements (n = 3, mean + s.d. plotted).

Biochemically-tuned Laminin-containing HA-oxime Hydrogels Interact with Cells

To mimic the heterogeneity of the extracellular matrix in breast cancer and enhance cell interaction with the HA-oxime hydrogels,[27] we mixed laminin-1 (Ln) with the polymers prior to gelation and found that it was retained in the gels obviating the need for covalent immobilization: Ln incorporated at either 75 or 250 μg·mL^{-1} was completely retained in hydrogels after 7 days, with no soluble Ln detected in the PBS supernatant (Fig. 2a). Given the large size of Ln (850 kDa), it was likely physically entrapped or entangled within the HA-oxime polymer chains, but may have also be retained by either (or both) electrostatic interactions between positively charged Ln and negatively charged hyaluronan-carboxylate groups[28] or reversible Schiff-base formation between basic lysine groups on laminin and HA-ketone/aldehyde groups.[29] The interactions between laminin and HA-oxime hydrogels did not alter the compressive modulus compared to HA-oxime only hydrogels thereby enabling the role of ECM proteins to be studied separately from mechanical properties (Figs. S8a).

To investigate cell-Ln interactions, we compared cell adhesion to HA-oxime gels with or without Ln and found more than 2-times more T47D luminal A breast cancer cells adhered to the surface of hydrogels containing 75 μg·mL^{-1} Ln, similar to Matrigel versus controls without Ln (Fig. 2b). With or without Ln, breast cancer cells encapsulated in HA-oxime hydrogels were equally viable and evenly distributed, and the size and number of spheroids were similar (Fig. S8b-i). Cells within the spheroids interacted with each other, as demonstrated by E-cadherin expression, a marker of tight junctions (Fig. 2c-d). Cells also interacted with the HA-oxime hydrogel through CD44, a hyaluronan receptor, and expressed β1-integrin, a Ln receptor (Fig. 2e-h). CD44 is essential to the growth of breast cancer cells and β1-integrin is involved in the PI3K pathway, which is upregulated in breast cancer and constitutes a drug target.[30] We observed some evidence of HIF-1α expression, a marker for either reactive oxygen species or hypoxia typically observed

10

in breast cancer tumours (Fig. 2i-j). The HIF-1α expression observed at the periphery of the spheroids has been observed in other cancer spheroids and likely represents reactive oxygen species versus hypoxia at the core because oxygen can diffuse though the ~70 μm diameter spheroids (Fig. S9).[31] Given the relevance of hyaluronan in breast cancer[32] and the interaction of cells with the HA-oxime hydrogels, we wondered whether culture in HA-oxime with or without laminin would impact the gene expression levels compared to those in Matrigel and conventional 2D TCPS.


Figure 2. Impact of laminin in HA-oxime hydrogels. (a) The amount of Ln retained in HA-oxime hydrogels crosslinked with PEGOA₄ quantified by ELISA after 7 days, Ln was not detected (nd) from supernatant 24 h after adding PBS to HA-oxime-Ln hydrogels (n = 3 independent samples;

11

mean + standard deviation plotted, no significant differences (ns), **$p<0.01$, one-way ANOVA, Tukey's post-hoc test). (b) Fold change in the number of breast cancer cells on HA-oxime gels crosslinked with $PEGOA_4$ containing Ln versus those on Matrigel (n = 3 independent studies; mean + standard deviation plotted, *$p<0.05$; one-way ANOVA, Tukey's post-hoc test). (c-j) Representative immunocytochemistry images of MDA-MB-468 cells encapsulated in HA-oxime hydrogels after 21 days stained for nuclei (with Hoechst, blue) and actin (with phalloidin which binds to F-actin, red) (c, d) E-cadherin, (e, f) CD44, (g, h) β_1 integrin and (i, j) HIF-1α.

HA-oxime Hydrogels Enable Spheroid Formation of 5 Different Breast Cancer Cell Lines and Patient-derived Primary Breast Cancer Cells

When cells from 5 different breast cancer cell lines were cultured for 21 days in HA-oxime hydrogels +/- Ln they formed spheroids, which was not observed in 2D culture (Fig. S10). These cells represent 4 breast cancer subtypes with different expression profiles of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): luminal A MCF7 and T47D (ER$^+$, PR$^+$, HER2$^-$), luminal B BT474 (ER$^+$, PR$^+$, HER2$^+$), HER2-overexpressing MDA-MB-231-H2N (ER$^-$, PR$^-$, HER2$^+$), and triple negative MDA-MB-468 (ER$^-$, PR$^-$, HER2$^-$) cells. By examining proliferation in 2D and 3D, and between different hydrogel cultures, we observed that all breast cancer cell lines exhibited similar proliferation rates in HA-oxime +/- Ln hydrogels compared to Matrigel except BT474 cells, where proliferation was increased in Matrigel (Fig. 3a). In addition, all cells formed spheroids of similar diameter ~100 μm, suitable for oxygen and nutrient penetration[33] at 21 days in HA-oxime hydrogels and Matrigel (Fig. 3b), indicating phenotypic equivalence at minimum.

Recent efforts to develop *in vitro* cancer models that recapitulate the features of human breast cancer for preclinical testing or personalized medicine have used poorly-defined Matrigel

12

to grow 3D tumour organoids. To test the HA-oxime hydrogel for these applications, we encapsulated patient-derived primary luminal B breast cancer cells in 3D therein and observed their survival and proliferation: the patient-derived cells grew as spheroids in the hydrogel but proliferated as monolayers on 2D TCPS (Fig. S11). Impressively, encapsulated primary breast cancer cells from a dissociated patient biopsy formed spheroids in both HA-oxime +/- Ln and Matrigel after 21 days of culture (Fig. 3c-f). It is possible that over the 21 days of culture within the 3D hydrogel, glucose and/or oxygen gradients will form and result in heterogeneity that more closely mimics the tumour microenvironment within the xenograft versus that of 2D TCPS. These results led us to perform a more extensive comparison of gene expression between the mouse xenografts and *in vitro* models in order to better understand the biological differences between these *in vitro* models.

Gene Expression of 5 Distinct Breast Cancer Cell Lines Cultured *In Vitro* vs. In Vivo Growth as Tumour Xenografts

In order to understand how breast cancer markers and drug-targetable pathways are impacted by culture platform, we benchmarked the gene expression of 5 cell lines cultured in HA-oxime +/- Ln against orthotopic mouse xenografts in NOD SCID gamma mice and compared them to those in Matrigel or 2D TCPS (Fig. S12, S13). In general, the gene expression of breast cancer cells cultured in either HA-oxime hydrogels +/- Ln or Matrigel were more similar to that of mouse xenograft models than cells cultured on 2D TCPS (Fig. 3g). Several genes were differentially expressed compared to tumour xenografts when cultured on 2D TCPS, but not when cultured in HA-oxime hydrogels, including epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (ERBB2) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) which are implicated in drug targetable pathways (Table S1). The

13

expression of both ERBB2 and EGFR can result in changes to cell phenotype and tumourigenicity, and may also influence response to therapy, including agents targeting these receptors directly.[34] In addition, patients with PIK3CA-positive breast tumours have shorter disease-free survival across all molecular subtypes indicating its potential as a therapeutic target.[35] Thus, these results further underscore the need to use representative 3D models to study breast cancer over traditional 2D culture.

A potential strategy for treating breast cancer beyond traditional kinase inhibitors includes emerging metabolic targets such as FASN, which is responsible for lipid synthesis. Currently, the FASN inhibitor TVB-2640 is being evaluated for the treatment of advanced breast cancer in a clinical trial.[36] Due to observed differences in cellular fatty acid and cholesterol content between 2D culture and xenograft models,[37] we hypothesized that the expression of lipid metabolic genes would be more similar in 3D cell culture than 2D culture relative to the xenograft tumours. The expression of FASN, which is responsible for lipid synthesis, and ATP-binding cassette transporter (ABCA1), which regulates intracellular phospholipid and cholesterol homeostasis, depended upon both cell line and culture system. For example, luminal A MCF7 cells had similar ABCA1 and FASN expression between tumour xenograft and HA-oxime hydrogel culture, but an upregulated FASN expression when cultured on 2D TCPS or Matrigel (Fig. 3g). This shows that FASN expression is influenced by the ECM and that gene expression levels of xenograft tumours for luminal A breast cancer were recapitulated using the HA-oxime hydrogel. However, HER2-overexpressing MDA-MB-231-H2N cells upregulated FASN and ABCA1 across all *in vitro* models, which suggests altered lipid metabolism and secretion compared to xenograft tumours. These differences in FASN expression were not observed for other breast cancer subtypes, which supports breast cancer subtype-dependent lipid metabolism in 2D.[38] Considering the similar gene

14

expression of breast cancer cells cultured in HA-oxime hydrogels and grown as xenograft tumours, we performed more rigorous benchmarking with a pan-cancer gene expression panel.


Figure 3. Evaluation of patient-derived and 5 different breast cancer cell lines in HA-oxime +/- Ln versus Matrigel and 2D TCPS. (a) Cell growth at day 7 relative to day 1 (n = 3; mean + s.d. plotted, *p<0.05, one-way ANOVA, Tukey's post-hoc test). (b) Tumour spheroid diameter after 21 days of culture for cells embedded in HA-oxime, HA-oxime-Ln or Matrigel (n = 3; mean + s.d. plotted, *p<0.05, one-way ANOVA, Tukey's post-hoc test). No spheroids were formed on 2D

TCPS. (c-f) Representative images of primary, patient breast cancer cells after 21 days of culture in (c) HA-oxime, (d) HA-oxime + Ln, (e) Matrigel or (f) 2D TCPS. Cells stained with phalloidin (binds to F-actin, shown in green) and Hoechst (nuclei, shown in blue); scale bar represents 50 µm. (g) Heat map gene expression of MCF7, T47D, BT474, MDA-MB-231-H2N, and MDA-MB-468 cells encapsulated in HA-oxime, HA-oxime-Ln, Matrigel, or cultured on 2D TCPS after 21 days and compared to the respective mouse xenograft tumours. Expression reported as the Log_2 ratio from qPCR with black indicating the greatest similarity (n = 3-5 independent studies; mean plotted).

Pan-Cancer Gene Expression Benchmarks *In Vitro* Breast Cancer Models

In order to better understand the predictive powers of 3D in vitro culture of breast cancer cells, we benchmarked 3 distinct cell lines, representing 3 different breast cancer subtypes, to tumour xenografts: luminal B (BT474); HER2-overexpressing (MDA-MB-231-H2N); and triple negative (MDA-MB-468). We cultured cells in 3D in HA-oxime, Matrigel or in 2D on TCPS and compared the gene expression panel of 730 cancer-related genes. Relative to tumour xenografts, we found that luminal B, BT474 cells had the fewest number of differentially expressed genes when cultured in HA-oxime gels (24 downregulated and 27 upregulated of 730 genes) compared to those cultured in Matrigel (63 downregulated and 135 upregulated) and on 2D TCPS (60 downregulated, 45 upregulated) (Fig. 4a, b, Table S2). Surprisingly, there were more differences when cells were cultured in Matrigel than on 2D TCPS relative to xenografts, which both reflects the unsuitability of Matrigel and demonstrates that 3D culture alone is insufficient for predictive drug screening.

We analyzed 12 pathways and driver genes by gene set variation analysis and found that BT474 cells cultured in Matrigel altered the expression of several pathways including JAK-STAT

16

and MAPK versus tumour xenografts whereas cells cultured in HA-oxime gels did not (Fig. 4c). This further motivates the use of representative, benchmarked 3D *in vitro* models, such as the HA-oxime hydrogel, to recapitulate gene expression and to evaluate new drug candidates against JAK-STAT and MAPK.[39]

Comparing the gene expression of MDA-MB-231-H2N tumours to 3D hydrogels and 2D culture, we found that fewer genes were differentially expressed when cells were grown in HA-oxime gels (16 downregulated, 12 upregulated) versus both Matrigel (28 downregulated, 21 upregulated) and 2D TCPS (33 downregulated, 29 upregulated) (Fig. 4d, e, Table S3). Altered gene expression of a therapeutic target in cells used in an *in vitro* drug screen would generate misleading data. Differences in the JAK-STAT pathway were identified between cells cultured in HA-oxime, Matrigel or 2D TCPS relative to the tumour xenografts after analyzing the pathways regulating cell survival and cell fate between the *in vitro* models and tumour xenografts of MDA-MB-231-H2N cells (Fig. 4f).

When triple-negative breast cancer (TNBC) MDA-MB-468 cells were cultured in HA-oxime gels, Matrigel or 2D TCPS, a similar number of genes were downregulated compared to the xenograft tumours (125, 134 and 122, respectively) while the number of upregulated genes was higher in 2D TCPS (94) versus HA-oxime and Matrigel (60 and 54 genes, respectively) (Fig. 4g, h, Table S4). Subsequent analysis of affected pathways revealed that the hedgehog pathway was altered when cultured in HA-oxime, Matrigel or 2D TCPS relative to the tumour xenografts (Fig. 4i). Since only 30% of triple-negative breast cancers involve paracrine hedgehog (Hh) signalling, which has been studied in the context of cancer-associated fibroblasts, co-culture models may be required to target this pathway.[40]

17

Our gene expression pathway analyses show that the JAK-STAT pathway was altered in both HER2$^+$ BT474 and MDA-MB-231-H2N cell lines when cultured in Matrigel or on 2D TCPS relative to xenograft and HA-oxime. This underlines the need to evaluate drugs targeting specific pathways on validated models. Remarkably, while Matrigel is thought to be the gold standard for in vitro culture, it has not been benchmarked previously and our data clearly demonstrate that it is sub-optimal. Overall, HA-oxime gels were the most similar to xenografts, with only 294 differentially expressed genes vs. 434 for Matrigel and 371 for 2D TCPS (Figure 4j, Fig. S14). The number of differentially expressed genes for the same cell lines was similar between HA-oxime and HA-oxime-Ln hydrogels (294 versus 308 genes, respectively) compared to the xenograft tumours (Fig. S14b). Thus, 3D culture reduces, but does not eliminate, differences in gene expression between 2D culture and xenografts. 3D culture in HA-oxime better emulates the gene expression profile of xenografts than culture in Matrigel.

Figure 4. Comparison of *in vitro* gene expression and pathway analysis for three breast cancer cell

lines relative to tumour xenografts in mice. (a, b) Venn Diagrams depicting the number genes

differentially expressed by BT474 cells cultured *in vitro* compared to xenografts. (c) Pathway specific expression correlation values and p-values by gene set variation analysis of BT474 cells cultured *in vitro* versus tumour xenografts. Altered pathways in cells cultured *in vitro* are shown above the dashed line. (d, e) Venn diagrams depicting the number genes differentially expressed by MDA-MB-231-H2N cells cultured *in vitro* compared to xenografts. (f) Pathway specific expression correlation values and p-values by gene set variation analysis of MDA-MB-231-H2N cells cultured *in vitro* versus tumour xenografts. Altered pathways in cells cultured *in vitro* are shown above the dashed line. (g, h) Venn Diagrams depicting the number genes differentially expressed by MDA-MB-468 cells cultured *in vitro* compared to xenografts. (i) Pathway specific expression correlation values and p-values by gene set variation analysis of MDA-MB-468 cells cultured *in vitro* versus tumour xenografts. Altered pathways in cells cultured *in vitro* are shown above the dashed line. Pathway specific expression correlation values and p-values by gene set variation analysis versus tumour xenografts. (j) Summary of all observed differentially expressed genes after culture in HA-oxime, Matrigel, or 2D TCPS versus mouse xenograft tumours for BT474, MDA-MB-231-H2N, and MDA-MB-468 cells (n = 3 except for BT474 cells grown in Matrigel where n = 4).

Evaluating Differences in Drug Response Between 2D and 3D Models

To understand if these differences in gene expression could influence cell response in drug screening, we specifically chose drugs that target pathways differentially expressed between xenograft and *in vitro* culture in Matrigel and 2D TCPS and that were not differentially expressed in HA-oxime (Table S4, S5). We tested a series of drugs that target the MAPK (such as Rac signaling) and JAK-STAT pathways of BT474 cells grown in HA-oxime vs. Matrigel and 2D TCPS.

20

BT474 cells treated with EHT-1864 (Rac inhibitor, targeting the MAPK/ERK pathway) were more responsive when cultured in HA-oxime than in Matrigel (Fig. 5a, Fig. S15). In addition, BT474 cells cultured in HA-oxime were more responsive to AZD6482 (PI3Kβ inhibitor involved in the JAK-STAT pathway) than those cultured in Matrigel or on 2D TCPS (Fig. 5b). To gain biological insight into the mechanism underlying the observed differences in drug responsiveness, we quantified the number of genes involved in MAPK and JAK-STAT signaling pathways with differential expression levels relative to tumour xenografts: cells cultured in HA-oxime had fewer differentially expressed genes (14 for MAPK and 4 for JAK-STAT) compared to cells cultured in both Matrigel (43 for MAPK and 29 for JAK-STAT) and on 2D TCPS (23 for MAPK and 10 for JAK-STAT) (Fig. 5c-e, red circles for MAPK and green circles for JAK-STAT). Together these results demonstrate the superiority of HA-oxime over Matrigel and 2D TCPS in drug screening where specific pathways are targeted.

Interestingly, cells cultured in HA-oxime were over tenfold more sensitive to maritoclax (Fig. S15c), an Mcl-1 inhibitor which prevents the normal anti-apoptotic signaling by Mcl-1 on the mitochondria resulting in apoptosis, with an IC_{50} of 0.59 μM than those cultured in 2D TCPS with IC_{50} of 5.5 μM (Fig. 5f). Moreover, primary, human patient tumour luminal B breast cancer cells were significantly more sensitive to maritoclax when cultured in 3D HA-oxime than those cultured on 2D TCPS as well, demonstrating both the potential of the HA-oxime hydrogels in personalized medicine and the importance of culture conditions in drug screening (Fig. S16). Maritoclax targets the apoptosis pathway as an inhibitor of anti-apoptotic protein Mcl-1 on the mitochondria. Regulators of this apoptosis pathway, BAD (pro-apoptotic) and BCL2 (anti-apoptotic), had decreased levels in BT474 cells cultured on 2D TCPS relative to 3D culture, which explains the observed differences in drug response (Fig. 5g).

21

We highlight the results of the *in vitro* drug screening performed with BT474 cells where IC$_{50}$ values differed between HA-oxime, Matrigel and 2D TCPS (Fig. 5h). Since the decision to test drugs in animal models of disease is often based on *in vitro* screening, maritoclax, EHT-1864 and AZD6482 would have been excluded based on culture in Matrigel and/or 2D TCPS, thereby reflecting the importance of culture in a representative matrix, such as HA-oxime. The differences between 2D and 3D culture of breast cancer cells are significant in terms of gene expression and drug response. While cell response did not always differ between the 3 culture conditions (as shown with ZSTK474 and afatinib, Fig. S15), to ensure comprehensive screening, a validated, representative system, like HA-oxime, is required.

Figure 5. Targeting pathways in BT474 breast cancer cells cultured *in vitro* with drugs. (a, b) IC_{50} values for BT474 cells cultured *in vitro* treated with (a) EHT 1864 targeting the MAPK pathway or (b) AZD6482 targeting the JAK-STAT pathway (n = 3 independent experiments; mean +

standard deviation plotted, *p<0.05, **p<0.01, by one-way ANOVA, Tukey's post-hoc test). (c-d) Volcano plots of differentially expressed genes involved in MAPK signalling (red), JAK-STAT signalling (green), both pathways (yellow), other (blue) and similarly expressed (white) when cultured in (c) HA-oxime, (d) Matrigel or on (e) 2D TCPS versus tumour xenografts. (f) IC_{50} values for BT474 and patient derived breast cancer cells cultured *in vitro* treated with maritoclax targeting the apoptosis pathway (n = 3 independent experiments; mean + standard deviation plotted, **p<0.01, ***p<0.001 by one-way ANOVA, Tukey's post-hoc test). (g) Gene expression counts of apoptosis signalling genes BAX, BAD and BCL2 for BT474 cells cultured *in vitro* or as tumour xenografts. (h) Summary of observed statistical differences in IC_{50} values from drug screening with EHT 1864 (which targets MAPK), AZD6482 (which targets JAK-STAT) and maritoclax (which targets apoptosis) with BT474 cells cultured in HA-oxime, Matrigel or on 2D TCPS. IC_{50} values that were statistically different depending on culture platform are shown in red while those which were not statistically different are shown in green.

To gain insight into the broader utility of the HA-oxime hydrogels with other cell types, we investigated the efficacy of erlotinib, an EGFR inhibitor, against TNBC MDA-MB-468 cells. Cells that were grown on 2D TCPS, in Matrigel or HA-oxime for 21 days and treated with erlotinib for 7 days had a significantly higher IC_{50} of 37.6 μM (p<0.01) compared to those cultured in 3D of ~4.5 μM (Fig. S17). MDA-MB-468 cells cultured on 2D were less sensitive to erlotinib than other cancer cell lines, despite its established effectiveness in breast cancer xenografts in mice,[41] further highlighting the importance of relevant screening assays.

Conclusions

3D cell culture has several features which make it attractive for drug screening, yet is limited by the use of Matrigel, which does not faithfully recapitulate the gene expression profile of the tumour

24

xenograft and is chemically ill-defined. The newly synthesized HA-oxime hydrogels have controlled and tunable gelation, mechanical properties, and chemical properties that mimic the breast ECM, which are not possible with 2D TCPS and limited with Matrigel. By benchmarking to the *in vivo* gold standard for the first time, we demonstrate that breast cancer cells grown in HA-oxime hydrogels most closely resemble orthotopic xenografts in terms of gene expression profiles of 3 distinct breast cancer subtypes. This impacts the value of in vitro drug screening. Formulating the HA-oxime hydrogels with laminin did not reduce the number of differentially expressed genes expressed by the breast cancer spheroids compared to the tumour xenografts. Our analysis of canonical signaling pathways using the gene expression data suggest breast cancer subtype-dependant changes to gene expression with culture platform. We demonstrated the ability to grow patient-derived breast cancer cells in HA-oxime hydrogels and thereby identify relevant drug candidates. Thus, hyaluronan-oxime hydrogels bridge the gap between 2D drug screening *in vitro* and *in vivo* mouse xenograft models, opening the door to personalized medicine and more predictive drug screening. To take full advantage of this opportunity, scale up and simultaneous screening of multiple drugs is required. This well-defined hydrogel platform opens up the possibility for more complex 3D models with co-culture of multiple cell types, thereby better emulating the complexity of tumours.

Acknowledgements

25

Methods

Detailed methods are presented in the Supplementary Information.

References

[1] S. P. Leelananda, S. Lindert, Beilstein J Org Chem 2016, 12, 2694; V. Malik, J. K. Dhanjal, A. Kumari, N. Radhakrishnan, K. Singh, D. Sundar, Methods 2017, 131, 10.

[2] Y. Li, E. Kumacheva, Sci Adv 2018, 4.

[3] N. Jacobi, R. Seeboeck, E. Hofmann, H. Schweiger, V. Smolinska, T. Mohr, A. Boyer, W. Sommergruber, P. Lechner, C. Pichler-Huebschmann, K. Onder, H. Hundsberger, C. Wiesner, A. Eger, Oncotarget 2017, 8, 107423.

[4] T. Hasan, B. Carter, N. Denic, L. Gai, J. Power, K. Voisey, K. R. Kao, J Clin Pathol 2015, 68, 746.

[5] C.-P. Day, G. Merlino, T. Van Dyke, Cell 2015, 163, 39.

[6] A. Ivascu, M. Kubbies, International journal of oncology 2007, 31, 1403; J. R. Todd, K. A. Ryall, S. Vyse, J. P. Wong, R. C. Natrajan, Y. Yuan, A. C. Tan, P. H. Huang, Oncotarget 2016, 7, 62939; Y. Imamura, T. Mukohara, Y. Shimono, Y. Funakoshi, N. Chayahara, M. Toyoda, N. Kiyota, S. Takao, S. Kono, T. Nakatsura, H. Minami, Oncology reports 2015, 33, 1837.

[7] F. Madoux, A. Tanner, M. Vessels, L. Willetts, S. Hou, L. Scampavia, T. P. Spicer, SLAS Discov 2017, 22, 516.

[8] E. R. Boghaert, X. Lu, P. E. Hessler, T. P. McGonigal, A. Oleksijew, M. J. Mitten, K. Foster-Duke, J. A. Hickson, V. E. Santo, C. Brito, T. Uziel, K. S. Vaidya, Neoplasia 2017, 19, 695.

[9] J. E. Sero, H. Z. Sailem, R. C. Ardy, H. Almuttaqi, T. Zhang, C. Bakal, Mol Syst Biol 2015, 11, 0790; M. F. Gencoglu, L. E. Barney, C. L. Hall, E. A. Brooks, A. D. Schwartz, D. C. Corbett, K. R. Stevens, S. R. Peyton, ACS Biomater Sci Eng 2018, 4, 410.

[10] R. Xu, J.-H. Mao, Integr Biol 2011, 3, 368; C. J. Lovitt, T. B. Shelper, V. M. Avery, BMC Cancer 2018, 18, 41.

[11] B. Weigelt, C. M. Ghajar, M. J. Bissell, Adv Drug Deliv Rev 2014, 69-70, 42.

[12] C. S. Hughes, L. M. Postovit, G. A. Lajoie, Proteomics 2010, 10, 1886.

[13] L. Lambricht, P. De Berdt, J. Vanacker, J. Leprince, A. Diogenes, H. Goldansaz, C. Bouzin, V. Préat, C. Dupont-Gillain, A. d. Rieux, Dent Mater 2014, 30, e349.

[14] P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Agren, R. Johansson, P. Hirvikoski, M. Eskelinen, V. M. Kosma, Am J Pathol 2000, 156, 529.

[15] A. Rizwan, M. Cheng, Z. M. Bhujwalla, B. Krishnamachary, L. Jiang, K. Glunde, NPJ Breast Cancer 2015, 1, 15017; J. R. Todd, K. A. Ryall, S. Vyse, J. P. Wong, R. C. Natrajan, Y. Yuan, A.-C. Tan, P. H. Huang, Oncotarget 2016, 7, 62939.

[16] H. Wang, D. Zhu, A. Paul, L. Cai, A. Enejder, F. Yang, S. C. Heilshorn, Advanced Functional Materials 2017, 27, 1605609.

[17] F. Saito, H. Noda, J. W. Bode, ACS chemical biology 2015, 10, 1026.

[18] S. A. Fisher, A. E. G. Baker, M. S. Shoichet, J Am Chem Soc 2017, 139, 7416.

[19] A. K. Jha, K. M. Tharp, S. Browne, J. Ye, A. Stahl, Y. Yeghiazarians, K. E. Healy, Biomaterials 2016, 89, 136.

[20] J. Kalia, R. T. Raines, Angew Chem Int Ed 2008, 47, 7523; C. Kascholke, T. Loth, C. Kohn-Polster, S. Möller, P. Bellstedt, M. Schulz-Siegmund, M. Schnabelrauch, M. C. Hacker, Biomacromolecules 2017, 18, 683.

[21] A. E. G. Baker, R. Y. Tam, M. S. Shoichet, Biomacromolecules 2017, 18, 4373.

[22] H.-H. Lin, H.-K. Lin, I. H. Lin, Y.-W. Chiou, H.-W. Chen, C.-Y. Liu, H. I. C. Harn, W.-T. Chiu, Y.-K. Wang, M.-R. Shen, M.-J. Tang, Oncotarget 2015, 6, 20946.

[23] M. Smolina, E. Goormaghtigh, Analyst 2016, 141, 620.

[24] M. J. Paszek, N. Zahir, K. R. Johnson, J. N. Lakins, G. I. Rozenberg, A. Gefen, C. A. Reinhart-King, S. S. Margulies, M. Dembo, D. Boettiger, D. A. Hammer, V. M. Weaver, Cancer cell 2005, 8, 241.

[25] K. R. Levental, H. Yu, L. Kass, J. N. Lakins, M. Egeblad, J. T. Erler, S. F. T. Fong, K. Csiszar, A. Giaccia, W. Weninger, M. Yamauchi, D. L. Gasser, V. M. Weaver, Cell 2009, 139, 891; A. Ansardamavandi, M. Tafazzoli-Shadpour, R. Omidvar, I. Jahanzad, J Mech Behav Biomed Mater 2016, 60, 234.

[26] L. Edjekouane, S. Benhadjeba, M. Jangal, H. Fleury, N. Gévry, E. Carmona, A. Tremblay, Oncotarget 2016, 7, 77276; H. Tan, H. Li, J. P. Rubin, K. G. Marra, Journal of tissue engineering and regenerative medicine 2011, 5, 790.

[27] A. S. Caldwell, G. T. Campbell, K. M. T. Shekiro, K. S. Anseth, Adv Healthc Mater 2017, 6, 1700254; S. Suri, C. E. Schmidt, Tissue engineering. Part A 2010, 16, 1703; Z.-N. Zhang, B. C. Freitas, H. Qian, J. Lux, A. Acab, C. A. Trujillo, R. H. Herai, V. A. Nguyen Huu, J. H. Wen, S. Joshi-Barr, J. V. Karpiak, A. J. Engler, X.-D. Fu, A. R. Muotri, A. Almutairi, Proc Natl Acad Sci 2016, 113, 3185.

[28] M. Rinaudo, Int J Biol Macromol 2008, 43, 444.

[29] S. E. Stabenfeldt, A. J. Garcia, M. C. LaPlaca, Journal of biomedical materials research. Part A 2006, 77, 718.

[30] S. Godar, T. A. Ince, G. W. Bell, D. Feldser, J. L. Donaher, J. Bergh, A. Liu, K. Miu, R. S. Watnick, F. Reinhardt, S. S. McAllister, T. Jacks, R. A. Weinberg, Cell 2008, 134, 62; K. To, A. Fotovati, K. M. Reipas, J. H. Law, K. Hu, J. Wang, A. Astanehe, A. H. Davies, L. Lee, A. L. Stratford, A. Raouf, P. Johnson, I. M. Berquin, H. D. Royer, C. J. Eaves, S. E. Dunn, Cancer Res 2010, 70, 2840; R. Castello-Cros, D. R. Khan, J. Simons, M. Valianou, E. Cukierman, BMC Cancer 2009, 9, 94.

[31] G. Wang, T. Zhao, X. Song, W. Zhong, L. Yu, W. Hua, M. M. Q. Xing, X. Qiu, Polymer Chemistry 2015, 6, 283; S. Riffle, R. N. Pandey, M. Albert, R. S. Hegde, BMC Cancer 2017, 17, 338.

[32] P. Heldin, K. Basu, B. Olofsson, H. Porsch, I. Kozlova, K. Kahata, J Biochem 2013, 154, 395; P. Auvinen, R. Tammi, V.-M. Kosma, R. Sironen, Y. Soini, A. Mannermaa, R. Tumelius, E. Uljas, M. Tammi, Int. J. Cancer 2013, 132, 531.

[33] E. Curcio, S. Salerno, G. Barbieri, L. De Bartolo, E. Drioli, A. Bader, Biomaterials 2007, 28, 5487.

27

[34] S. Ingthorsson, K. Andersen, B. Hilmarsdottir, G. M. Maelandsmo, M. K. Magnusson, T. Gudjonsson, Oncogene 2015, 35, 4244.

[35] M. A. Aleskandarany, E. A. Rakha, M. A. Ahmed, D. G. Powe, E. C. Paish, R. D. Macmillan, I. O. Ellis, A. R. Green, Breast Cancer Res Treat 2010, 122, 45.

[36] J. A. Menendez, R. Lupu, Expert opinion on therapeutic targets 2017, 21, 1001; M. E. Monaco, Oncotarget 2017, 8, 29487.

[37] N. Mori, F. Wildes, T. Takagi, K. Glunde, Z. M. Bhujwalla, Front Oncol 2016, 6, 262.

[38] A. N. Lane, J. Tan, Y. Wang, J. Yan, R. M. Higashi, T. W. M. Fan, Metab Eng 2017, 43, 125.

[39] M. García-Aranda, M. Redondo, International journal of molecular sciences 2017, 18, 2543.

[40] M. N. Hui, A. Cazet, B. Elsworth, D. Roden, T. Cox, J. Yang, A. McFarland, N. Deng, C.-L. Chan, S. O'Toole, A. Swarbrick, Journal of Clinical Oncology 2018, 36, e24216.

[41] F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, N. T. Ueno, Mol Cancer Ther 2007, 6, 2168; Y.-K. I. Lau, X. Du, V. Reyannavar, B. Hopkins, J. Shaw, E. Bessler, T. Thomas, M. M. Pires, M. Keniry, R. E. Parsons, S. Cremers, M. Szabolcs, M. A. Maurer, Oncotarget 2014, 5, 10503.

Revised manuscript - highlighted

Click here to access/download
Production Data
adma.201901166 Manuscript Highlighted.docx

Table of Content Image

Click here to access/download
Production Data
TOC Benchmarking.tif

Click here to access/download

Production Data
adma.201901166 Supplementary.docx

Click here to access/download
Production Data
adma.201901166 Summary.docx